<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03670043</url>
  </required_header>
  <id_info>
    <org_study_id>1005965</org_study_id>
    <nct_id>NCT03670043</nct_id>
  </id_info>
  <brief_title>Tolerance &amp; Responsiveness Improvement for Metformin (TRIM)</brief_title>
  <official_title>Tolerance &amp; Responsiveness Improvement for Metformin (TRIM): Open-label, Parallel-group Randomized Trial, Phase 4</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>West Side Institute for Science and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>West Side Institute for Science and Education</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal is to explore the hypothesis that prebiotic fiber Psyllium will ameliorate
      diarrhea in African American men (AAM) with Type2 Diabetes Mellitus (T2D).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2019</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Birmingham Irritable Bowel Syndrome (IBS) Symptom Questionnaire</measure>
    <time_frame>3 months</time_frame>
    <description>This scale is based on symptoms that frequently occur in IBS cases, examines abdominal discomfort status, stool properties, and defecation feelings. The scale includes a total of 11 items, with 6 possible grades for each item that range from 0 points (never having this symptom) to 5 points (the symptom is always present). The total score is the sum of the scores for each item. The Total score is used. No &quot;subscale&quot; is used. Total range is minimum=0, maximum=55. The higher values represent a worse outcome.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Metformin ER</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects developing GI-related symptoms with metformin will be randomized to Metformin Extended Release (ER)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Psyllium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects developing GI-related symptoms with metformin will be randomized to Psyllium</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psyllium powder</intervention_name>
    <description>To evaluate whether Psyllium will alleviate diarrhea</description>
    <arm_group_label>Psyllium</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Extended Release Oral Tablet</intervention_name>
    <description>Metformin Extended Release Oral Tablet is standard of care for diarrhea in patients taking metformin</description>
    <arm_group_label>Metformin ER</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Male (M)

          2. African American (AA) race

          3. Age 20-70 years

          4. BMI 28-59 kg/m2

          5. T2D

          6. A1c 6.5 - 8.9%

          7. eGFR =/&gt; 30

          8. Drug-na√Øve or use Glipizide or newly started on Metformin (within 2 weeks).

        Exclusion criteria

          1. Chronic kidney disease stage 3b, 4 and 5 (eGFR &lt; 30)

          2. Insulin use

          3. Oral steroids use (inhalers and creams are allowed)

          4. Antibiotic use within the last month

          5. Artificial heart valves

          6. Hospitalization for chronic condition within 6 months prior to the study

          7. History, manifestations or medications of significant metabolic, hepatic, renal,
             hematological, pulmonary, cardiovascular, gastrointestinal, urological, neurological,
             psychiatric/ psychological disorders, or social circumstances which in the opinion of
             the investigator would be expected to interfere with the study or increase risk to the
             subject.

          8. Use of other antidiabetic drugs (except glipizide and metformin).

          9. Acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without
             coma.

        Additional Exclusion criteria for subjects who previously used Metformin:

          1. Previous severe allergic reaction to metformin hydrochloride, such as angioedema.

          2. Previous Metformin intolerance causing significant diarrhea or GI-upset. Would not
             exclude participants who had history of mild diarrhea with metformin use.

          3. Previous side effects that the subject feels were related to Metformin and the subject
             is not interested to re-try metformin.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barengolts</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jesse Brown VA Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barengolts</last_name>
    <phone>312-569-7651</phone>
    <email>Elena.Barengolts@va.gov</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jesse Brown VA Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akbar</last_name>
      <phone>312-569-6430</phone>
      <email>Arfana.Akbar@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>September 11, 2018</study_first_submitted>
  <study_first_submitted_qc>September 11, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2018</study_first_posted>
  <last_update_submitted>May 21, 2020</last_update_submitted>
  <last_update_submitted_qc>May 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Jesse Brown VA Medical Center</investigator_affiliation>
    <investigator_full_name>Elena Barengolts</investigator_full_name>
    <investigator_title>Chief, Section of Endocrinology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Psyllium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

